Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer

Rillamas-Sun, E., Kwan, M. L., Iribarren, C., Cheng, R., Neugebauer, R., Rana, J. S., Nguyen-Huynh, M., Shi, Z., Laurent, C. A., Lee, V. S., Roh, J. M., Huang, Y., Shen, H., Hershman, D. L., Kushi, L. H., & Greenlee, H. (2023). Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer. Breast Cancer Research and Treatment, 201(1), 117–126. https://doi.org/10.1007/s10549-023-06997-x
Authors:
Eileen Rillamas-Sun
Marilyn L Kwan
Carlos Iribarren
Richard Cheng
Romain Neugebauer
Jamal S Rana
Mai Nguyen-Huynh
Zaixing Shi
Cecile A Laurent
Valerie S Lee
Janise M Roh
Yuhan Huang
Hanjie Shen
Dawn L Hershman
Lawrence H Kushi
Heather Greenlee
Affiliated Authors:
Dawn L Hershman
Columbia Affiliation:
Subjects:
Breast Neoplasms (MeSH)
Hypertension (MeSH)
Author Keywords:
aromatase inhibitors
cancer survivors
cardiometabolic risk
cardiovascular disease
endocrine therapy
tamoxifen
elink
Publication Type:
Article
Unique ID:
10.1007/s10549-023-06997-x
PMID:
37326764
DOI:
10.1007/s10549-023-06997-x
Journal:
Breast Cancer Research and Treatment
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record

Record Created: